Zacks Research Has Pessimistic Outlook of A Q1 Earnings

Agilent Technologies, Inc. (NYSE:A) – Equities researchers at Zacks Research dropped their Q1 2026 earnings estimates for Agilent Technologies in a note issued to investors on Monday, December 15th. Zacks Research analyst Team now anticipates that the medical research company will post earnings of $1.36 per share for the quarter, down from their previous forecast of $1.38. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.58 per share. Zacks Research also issued estimates for Agilent Technologies’ Q2 2026 earnings at $1.40 EPS, Q3 2026 earnings at $1.46 EPS, Q4 2026 earnings at $1.68 EPS, FY2026 earnings at $5.90 EPS, Q1 2027 earnings at $1.52 EPS, Q4 2027 earnings at $1.77 EPS, FY2027 earnings at $6.48 EPS and FY2028 earnings at $7.30 EPS.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 EPS for the quarter, topping the consensus estimate of $1.58 by $0.01. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. The company had revenue of $1.86 billion during the quarter, compared to the consensus estimate of $1.83 billion. During the same period last year, the firm earned $1.46 EPS. Agilent Technologies’s revenue for the quarter was up 9.4% on a year-over-year basis. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS.

Other analysts have also recently issued research reports about the company. Bank of America increased their price objective on Agilent Technologies from $150.00 to $165.00 and gave the stock a “neutral” rating in a report on Tuesday, November 25th. Barclays upgraded Agilent Technologies from an “equal weight” rating to an “overweight” rating and set a $165.00 price target on the stock in a research report on Monday. Evercore ISI raised their price objective on shares of Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a research report on Tuesday, October 7th. TD Cowen boosted their price objective on shares of Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Finally, Wells Fargo & Company increased their target price on shares of Agilent Technologies from $150.00 to $175.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 25th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and an average target price of $161.77.

Agilent Technologies Trading Up 0.2%

NYSE:A opened at $136.88 on Wednesday. Agilent Technologies has a 1 year low of $96.43 and a 1 year high of $160.27. The stock’s fifty day moving average price is $145.43 and its two-hundred day moving average price is $129.76. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.96 and a quick ratio of 1.52. The company has a market cap of $38.81 billion, a P/E ratio of 29.95, a P/E/G ratio of 3.97 and a beta of 1.27.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Flynn Zito Capital Management LLC raised its stake in Agilent Technologies by 3.2% during the 3rd quarter. Flynn Zito Capital Management LLC now owns 2,257 shares of the medical research company’s stock worth $290,000 after acquiring an additional 69 shares during the period. Forum Financial Management LP increased its stake in shares of Agilent Technologies by 2.5% in the third quarter. Forum Financial Management LP now owns 2,921 shares of the medical research company’s stock worth $375,000 after purchasing an additional 70 shares in the last quarter. Gabelli Funds LLC raised its position in shares of Agilent Technologies by 1.1% during the 3rd quarter. Gabelli Funds LLC now owns 6,620 shares of the medical research company’s stock valued at $850,000 after purchasing an additional 74 shares during the period. Fiduciary Trust Co lifted its stake in shares of Agilent Technologies by 1.6% during the 3rd quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock valued at $633,000 after buying an additional 77 shares in the last quarter. Finally, Wedmont Private Capital increased its stake in Agilent Technologies by 2.3% in the 3rd quarter. Wedmont Private Capital now owns 3,630 shares of the medical research company’s stock worth $503,000 after buying an additional 81 shares in the last quarter.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 12,490 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $150.00, for a total value of $1,873,500.00. Following the transaction, the chief executive officer owned 33,448 shares of the company’s stock, valued at approximately $5,017,200. This represents a 27.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 3,000 shares of the business’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $154.99, for a total value of $464,970.00. Following the sale, the vice president owned 31,846 shares of the company’s stock, valued at approximately $4,935,811.54. This represents a 8.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 16,401 shares of company stock worth $2,468,962.

Agilent Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 28th. Investors of record on Tuesday, January 6th will be issued a $0.255 dividend. The ex-dividend date of this dividend is Tuesday, January 6th. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.25. This represents a $1.02 annualized dividend and a dividend yield of 0.7%. Agilent Technologies’s dividend payout ratio is presently 21.66%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.